XL BCR/ABL1/ASS
The XL BCR/ABL1/ASS probe is specific for the t(9;22). The orange labeled probe hybridizes to an extended region at the ABL1 locus on 9q34 and a green labeled probe hybridizes specifically to extended regions at the BCR gene on 22q11. A blue (aqua) labeled probe hybridizing to the ASS1 (formerly ASS) region is added to analyse deletions at 9q34 which can be associated with t(9;22).
Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL1 gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL1 active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.
Deletions at the t(9;22) breakpoint regions, found in 5% of CML patients with a Ph translocation, have been associated with resistance to treatments in patients receiving tyrosine kinase inhibitors.
Cena za kus: pro registrované
Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL1 gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL1 active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.
Deletions at the t(9;22) breakpoint regions, found in 5% of CML patients with a Ph translocation, have been associated with resistance to treatments in patients receiving tyrosine kinase inhibitors.
Cena za kus: pro registrované
